Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel Drugs - PubMed
4 hours ago
- #CLL treatment
- #novel therapies
- #refractory leukemia
- Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries.
- Targeted therapies like BTK inhibitors and BCL-2 inhibitors have transformed CLL treatment, but resistance leads to double refractory disease.
- Novel treatments for double refractory CLL include noncovalent BTK inhibitors (e.g., pirtobrutinib), BTK degraders, bispecific antibodies, and CAR T-cell therapies.
- Lisocabtagene maraleucel, a CAR T-cell therapy, has FDA approval for double refractory CLL, offering a potentially curative option.
- Current clinical trials are evaluating these emerging approaches to address the urgent unmet need in double refractory CLL.